

Preliminary figures for fiscal 2011: SSB continues on track for profitable growth

Goettingen, February 2, 2012

€ in millions Unaudited figures	2011	2010	Growth in %	Growth in %, const. currencies
Order intake	500.2	442.6	13.0	14.3
Sales revenue	477.3	432.9	10.2	11.5
• Europe ¹⁾	244.6	226.3	8.1	8.2
• North America ¹⁾	117.3	114.3	2.6	7.6
• Asia Pacific ¹⁾	96.7	74.6	29.6	28.7
• Other Markets ¹⁾	18.7	17.8	5.3	5.4
EBITA ²⁾	83.5	70.0	19.3	
EBITA margin ²⁾	17.5%	16.2%	+130bps ⁴⁾	
Net profit ^{2) 3)}	52.3	45.2	15.7	
Earnings per share in € ^{2) 3)}	3.41	2.81	21.5	

¹⁾ According to customers' location ²⁾ Underlying ³⁾ Excluding amortization ⁴⁾ Basis points

The Sartorius Stedim Biotech Group uses earnings before interest, taxes and amortization (EBITA) as the key figure for measuring performance and profitability of the Group. Amortization refers only to any potential amortization of goodwill and of the intangible assets measured within the scope of purchase price allocation according to IFRS 3 "Business Combinations". The key indicator "underlying EBITA" corresponds to the EBITA adjusted for non-operating items.

Double-digit growth in order intake and sales revenue

In 2011, Sartorius Stedim Biotech (SSB), a leading supplier for the biopharmaceutical industry, posted dynamic top-line growth. Single-use products again fueled these gains. Due to high demand from Asia, the equipment business also contributed to this expansion. From a regional perspective, Asia led growth, boosting its sales revenue by more than 28%, while Europe and North America both reported upper single-digit increases (all figures from the regions in constant currencies).

Profitability further increased

Sartorius Stedim Biotech again achieved an overproportionate rise in earnings. Mainly driven by economies of scale, underlying EBITA improved by 19.3% to 83.5 million euros. Its respective margin rose from 16.2% to 17.5%. Extraordinary expenses totaled 4.7 million euros and were mainly related to the optimization of company sites and other corporate projects. Underlying earnings per share were at 3.41 euros, up from 2.81 euros in 2010.

All key financial indicators at a comfortable level

In 2011, SSB generated an operating cash flow of 60.6 million euros compared to 72.8 million euros in 2010. Net debt decreased from 102.8 million euros to 100.1 million euros. Reflected by an equity ratio of 54.9, a gearing ratio of 0.3 and a ratio of net debt to underlying EBITDA of 1.0, the financial position of the Sartorius Stedim Biotech Group remains very strong.

Positive outlook for 2012

Positive business development is expected to continue in the current year. For 2012, SSB projects sales revenue to grow by about 6% to 8% in constant currencies. Along with growth in sales, underlying EBITA as well is targeted to rise at a rate of approximately 6% to 8%.

The figures given above are subject to a final audit by statutory auditors.

This press release contains statements about the future development of the Sartorius Stedim Biotech Group. We cannot guarantee that the content of these statements will actually apply because these statements are based upon assumptions and estimates that harbor certain risks and uncertainties.

Conference call and webcast

Joachim Kreuzburg, CEO and Chairman of the Board of the Sartorius Stedim Biotech Group, will discuss the results with analysts and investors on Thursday, February 2, 2012, at 3:30 p.m. Central European Time (CET), in a webcast teleconference. You may dial into the teleconference starting at 3:15 p.m. CET at the following numbers:

Germany: +49 (0)69 2222 34066

France: +33 (0)1 70 48 01 63

UK: +44 (0)20 7660 0009

USA: +1 646 254 3370

The dial-in code is: 5634610; to view the webcast or presentation, log onto:

<http://www.sartorius-stedim.com>

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of "turning science into solutions." Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 2,850 people, and in 2011 earned sales revenue of 477.3 million euros according to preliminary figures.

Contact

Petra Kirchhoff

Vice President of Group Corporate Communications

+49 (0)551.308.1686

petra.kirchhoff@sartorius.com